Search Results
Keyword:Pluvicto
Aktis Oncology Expands Clinical Enrollment for Actinium-Based Radiopharmaceuticals
Recently, Aktis Oncology of the United States disclosed the latest expanded enrollment arrangements for two clinical studies of innovative targeted radiopharmaceuticals based on Actinium-225. While continuing to advance the established dose-escalation trials, the company has added dedicated supplementary enrollment cohorts at selected dose levels for AKY-1189 targeting Nectin-4 and AKY-2519 targeting B7-H3, respectively, aiming to comprehensively observe the safety, tolerability, and preliminary antitumor activity of the drugs in specific patient populations, and to accumulate detailed data for subsequent large-scale clinical development. In terms of specific clinical progress, the Nectin-4-targeting AKY-...
2026-11-16
US FDA Approves Pluvicto Expanded Indication for Treatment of PSMA-Positive Metastatic Hormone-Sensitive Prostate Cancer
On July 31, 2026, Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor (ARPI) for the treatment of patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naive/sensitive prostate cancer. This disease is commonly referred to as metastatic hormone-sensitive prostate cancer (mHSPC). The approval is based on results from the Phase III PSMAddition trial. The study showed that compared with standard of care alone, namely ARPI combined with androgen deprivation therapy (ADT), Pluvicto plus standard of care reduced the risk of disease progression or death by...
2026-08-03